
About Soleno Therapeutics Inc
Soleno is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases based in Redwood City, CA.
At Soleno, we are driven by the unique and multi-faceted needs of the PWS community. Like these individuals, resilience is part of who we are – it is in our chromosomes – and our team is made up of exceptional colleagues whose collective efforts are woven together to deliver meaningful outcomes, both professionally and for those living with PWS.
We value collaboration, integrity, and respect. These characteristics have allowed us to forge strong, authentic bonds with the caregivers, patients, health care professionals (HCPs) and community members we serve. We are proud to work alongside them every step of the way.
Our employees are our greatest asset, and we're expanding across functions during this pivotal time. We invite you to join us in making an impact—and making history. We all share the most important goal of bringing solutions to the PWS community.
of Job (brief description)
Soleno Therapeutics is seeking a detail-oriented and proactive Accounts Payable & Payroll Specialist to support daily accounting operations. This role will manage full-cycle accounts payable, payroll administration, expense reimbursements, credit card processing, vendor maintenance, and contribute to month-end close. The Specialist will partner closely with the AP Manager and the broader Finance team to ensure accuracy, timeliness, and compliance across financial workflows.
Responsibilities
Qualifications
Salary Range: $85,000 - $110,000 annually
(Actual salary at the time of hire may vary and may be above or below the range based on various factors, including, but not limited to, the candidate’s relevant qualifications, skills, and experience, as well as the location where this position may be filled.)

At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more information, please visit soleno.life.